ArticleBritish journal of cancer1997
Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance.
Article in British journal of cancer, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 86 citations in OpenAlex.
- Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.Annals of oncology : official journal of the European Society for Medical Oncology · 2008Trial
- Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer.British journal of cancer · 2026Article
- FGFR‑related phenotypic and functional profile of CAFs in prognostication of breast cancer (Review).International journal of oncology · 2024Review
- The interaction of platelet-related factors with tumor cells promotes tumor metastasis.Journal of translational medicine · 2024Review
- Expression-Based Diagnosis, Treatment Selection, and Drug Development for Breast Cancer.International journal of molecular sciences · 2023Article
- Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment.Journal of Cancer · 2020Review
- Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer.Hormones & cancer · 2018Article
- The Influence of Biomaterials on Cytokine Production in 3D Cultures.Biomacromolecules · 2017Article
- Antiangiogenic mechanisms and factors in breast cancer treatment.Journal of carcinogenesis · 2016Review
- The -553 T/A polymorphism in the promoter region of the FGF2 gene is associated with increased breast cancer risk in Polish women.Archives of medical science : AMS · 2015Article
- TGFβ signaling in myeloid cells regulates mammary carcinoma cell invasion through fibroblast interactions.PloS one · 2015Article
- Ligand-dependent corepressor contributes to transcriptional repression by C2H2 zinc-finger transcription factor ZBRK1 through association with KRAB-associated protein-1.Nucleic acids research · 2014Article
- CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling.British journal of cancer · 2012Article
- Basic fibroblast growth factor in an animal model of spontaneous mammary tumor progression.Oncology reports · 2012Article
- Plasma VEGF levels in breast cancer patients with and without metastases.Oncology letters · 2010Article
- Review
- Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance.Journal of translational medicine · 2008Article
- The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer.Breast cancer research : BCR · 2004Review
- FGF signaling inhibits the proliferation of human myeloma cells and reduces c-myc expression.BMC cell biology · 2003Article
- Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma.British journal of cancer · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper examines the expression of fibroblast growth factor 2 (FGF-2) in the malignant human breast. Semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used to assess the level of expression of FGF-2 in a series of 51 patients clinically followed up for a median of 84 months (Luqmani et al, 1992). Immunohistochemistry and Western blotting were used to show that the level of FGF-2 in breast tissues correlated with the amount of FGF-2 mRNA. FGF-2 was present in both malignant and non-malignant breast, although less was expressed in malignant tissues as determined by all three methods. Immunohistochemistry on frozen sections of breast tissue showed expression of FGF-2 in myoepithelial and epithelial cells in non-malignant samples and generally lower or undetectable levels of staining in malignant epithelial cells. The results obtained by immunohistochemistry correlated well with RT-PCR data showing similar levels of FGF-2 and FGF-2 mRNA expression in samples. No correlation was found between FGF-2 mRNA expression and T stage, nodal status or oestrogen receptor status. However, Kaplan-Meier survival plots show that higher levels of FGF-2 are associated with improved overall and disease-free survival. We suggest that FGF-2 expression may have value as a prognostic indicator in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.